Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Molecular basis of disease > Hormone-dependant cancers: Prostate cancer > Flashcards

Hormone-dependant cancers: Prostate cancer Flashcards

1
Q

main function of the prostate

A

produce prostatic fluid that creates semen when mixed with the sperm produced by the testes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What type of gland is a prostate gland

A

an EXOCRINE GLAND

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are the phases of Prostate gland development

A

hormone-independent from embryonic development up to puberty
enlargement during puberty
hormone-dependent maintenance thereafter in adulthood

And – reactivation of prostate growth in old age – leading to hyperplasia and prostate cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Development of Prostate Abnormalities

A

Inflammation, e.g. due to infection
- Prostatitis - linked to infertility

Dysregulated growth of prostate

  • Benign: Benign Prostatic Hyperplasia (BPH)
  • Malignant: Prostate Cancer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Symptoms of Prostate abnormalities (including cancer)

A
  • frequent trips to urinate
  • poor urinary stream
  • urgent need to urinate
  • hesitancy whilst urinating
  • lower back pain
  • blood in the urine (rare)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Where does prostate cancer start?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Detecting Prostate Cancer

A

Digital rectal examination (DRE)

PSA test (Blood sample: antibody-based assay
)

Ultrasound

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the Prostate Cancer staging

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

N+: Tumour in lymph nodes

A

N0 =. No cancer cells found in any lymph nodes

N1 = 1 positive lymph node < 2cm across

N2 = >1 positive lymph node or 1 between 2-5cm across

N3 = Any positive lymph node > 5 cm across

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

M+: Metastatic (has the cancer metastasised)

A

M1a = Non-regional lymph nodes

M1b = bones

M1c = Other sites

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Histology of Prostate Cancer

A

Loss of glandular structure / irregular structure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Prostate Cancer Grading

A

TheGleason grading systemis used to help evaluate theprognosisof men using prostate biopsy samples.

The samples are examined by a clinical histologist.

Prostate cancer staging predicts prognosis and helps guide therapy.

Cancers with a higher Gleason score are more aggressive and have a worse prognosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Prostate cancer treatments

A
  • “Watchful waiting” = Low grade tumour, older patients
  • Radical prostatectomy = Stage T1 or T2 (confined to prostate gland)
• Radical radiotherapy = External up to T3 (spread past capsule)
Internal implants (brachytherapy) for T1/2

• Hormone therapy = Metastatic prostate cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Current Therapies for Prostate Cancer

A

Watchful weighting
For older men when
unlikely cancer will affect their natural lifespan.
If the cancer is in its early stages and not causing symptoms, you may decide to delay treatment and wait to see if any symptoms of progressive cancer develop.

Active surveillance
Aims to avoid unnecessary treatment of harmless cancers while still providing timely treatment for men who need it.
Active surveillance involves having regular PSA tests, MRI scans and sometimes biopsies to ensure any signs of progression are found as early as possible.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Risk Factors for Prostate Cancer

A 
Age
Race / ethnicity
Geography
Family History
Gene Changes / Inherited
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Other general risk factors

A

Diet - Men who eat a lot of dairy products

Obesity -obese men have a lower risk of getting a low-grade (slower growing) form of the disease, but a higher risk of getting more aggressive (faster growing) prostate cancer.

Chemical exposures

Inflammation of the prostate - Prostatitis (inflammation of the prostate gland)

Sexually transmitted infections - they can lead to inflammation of the prostate.

17
Q

Prostate Cancer Gene Mutations

A

There are several genes associated with prostate cancer

e.g. BRCA1 mutations and PTen loss
Men with lynch syndrome

18
Q

PTen

A

PTEN is a phosphatase that antagonizes the phosphatidylinositol 3-kinase signalling pathway.
As PTEN is the only known 3′ phosphatase counteracting the PI3K/AKT pathway.
Loss of PTen results in increased growth factor signalling.

19
Q

TMPRSS2 – ERG fusion

A

TMPRSS2-ERG fusion gene is the most frequent, present in 40% - 80% of prostate cancers in humans.

20
Q

What does the growth and development of the prostate gland depend on…

A
  • the presence of androgens (male hormones).

- The most common is testosterone (produced in the testes)

21
Q

Histology of Prostate gland

A

Brown staining for Androgen Receptor expression in the luminal epithelial cells

22
Q

Androgen Receptor (AR) signalling

A

AR is located in the cytoplasm associated with many chaperone proteins.

Testosterone is converted to a more potent agonist as it crosses into the prostate
Dihydrotestosterone (DHT) then binds the AR by an enzyme

It then binds the AR with a high affinity, causing the AR to be activated and dimerised.

The AR translocates into the nucleus to bind Androgen response element in the DNA sequence. It recruits co-activators

This will lead to target protein generation and thus cell growth.

23
Q

Targeting AR in Prostate Cancer

A

The prostate gland is an androgen sensitive and dependent tissue
Prostate cancer cells retain this sensitivity and dependency – androgens are a key driver of prostate cancer growth.
Therefore, this can be used as an inherent vulnerability that can be exploited for treatment.
Switch off AR signalling, switch off the the cancer growth.

AR targeting is the “Achilles Heel” of prostate cancer.

24
Q

Inhibition of Testosterone Synthesis

A

The adrenal androgen production can be inhibited, thus depriving the testes of testosterone precursors.

25
Q

Abiraterone-(acetate)

A

Can inhibit the two main enzymes required to make androgens

26
Q

What is the control of hormone production? (testosterone)

A

GnRH secreted from hypothalamus triggers pituitary to release FSH and LH which circulate in the blood to reach testes to stimulate more testosterone. The hypothalamus is sensitive to testosterone levels and will secrete more if insufficient levels – Feedback loop.

Synthetic peptides interrupt the hypothalamic-pituitary axis.
Goserelin – super agonist
Abarelix – antagonist

Overall the actions of superagonists and antagonists are similar – they depress testosterone production in the testes

27
Q

Inhibition of Testosterone Conversion to DHT

A

Agent can be used to interrupt conversion from Testosterone à DHT. This agent is called Finasteride or Dutasteride (Avodart).

Finasteride resembles an androgenic intermediate which can be used to inhibit 5 alpha-reductase enzyme and stop DHT production.

More commonly 5 alpha-reductase inhibitors are used for Benign Prostate Hyperplasia (BPH).

28
Q

Competitive inhibitors of androgen binding to the receptor

A

Competitive anti-androgens / androgen blockers

Compete for active site

Bicalutamide
Enzalutamide
Flutamide
Nilutamide

29
Q

Why do hormone therapies for cancer over time fail?

A

Homogenous cancer cells develop various mechanisms to overcome hormonal starvation.

30
Q

Mechanism #1 Hormone overproduction / or local synthesis

A

Some breast and prostate advanced tumour start to synthesise their own steroid hormones.

31
Q

Mechanism #2 - Ligand binding site mutations

A

Ligand binding site mutations make the receptors promiscuous

allows other hormones to bind

32
Q

Mechanism #3 - Receptor Amplification

A

Signal amplification, and increased sensitivity to low hormone levels

33
Q

Mechanism #4 - Receptor phosphorylation / activation in the absence of ligand

A

Cross over with other signal pathways e.g. growth factors can phosphorylate and activate receptors
- Prevalent for breast cancers

34
Q

Mechanism #5 - Androgen Receptor transcript variants: activation in the absence of ligand

A

e.g.

AR – variant 7 (V7)

Truncated AR without
C terminus

Active without ligand in prostate cancer

35
Q

Mechanism #6 - Receptor bypass – unknown mechanisms

A

Possible switch to

Other transcription factors, or oncogenes

36
Q

Mechanism #7 - Receptor cofactor amplification

A

Cofactor amplification can amplify the signal from steroid receptors in response to a low level of steroid hormone.

37
Q

Mechanism #8 - Antagonists become agonists via LBD mutations

A

Antagonists used for prostate cancer treatment can become potent activators of a mutant androgen receptor.

Molecular basis of disease (31 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions